ICU Medical (NASDAQ:ICUI) Raised to “Buy” at Wall Street Zen

ICU Medical (NASDAQ:ICUI) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Monday.

Several other research firms also recently commented on ICUI. KeyCorp increased their target price on shares of ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Piper Sandler upped their target price on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $175.67.

ICU Medical Stock Up 0.7%

Shares of ICU Medical stock opened at $156.17 on Monday. The company has a current ratio of 2.45, a quick ratio of 1.19 and a debt-to-equity ratio of 0.62. The company has a market cap of $3.86 billion, a P/E ratio of -503.76 and a beta of 0.80. The stock has a 50-day moving average price of $145.37 and a 200 day moving average price of $132.12. ICU Medical has a 1 year low of $107.00 and a 1 year high of $175.51.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The firm had revenue of $533.30 million for the quarter, compared to the consensus estimate of $511.46 million. During the same period in the previous year, the firm posted $1.59 earnings per share. The firm’s revenue was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, analysts expect that ICU Medical will post 4.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Virginia Ruth Sanzone sold 930 shares of ICU Medical stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total value of $132,376.20. Following the completion of the sale, the vice president directly owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. This trade represents a 14.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elisha W. Finney sold 1,285 shares of ICU Medical stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the sale, the director owned 3,995 shares of the company’s stock, valued at approximately $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of ICU Medical

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its holdings in ICU Medical by 2.5% in the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock worth $1,297,000 after purchasing an additional 229 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in ICU Medical by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after acquiring an additional 560 shares in the last quarter. United Services Automobile Association acquired a new stake in shares of ICU Medical in the 1st quarter valued at approximately $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of ICU Medical by 32.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock valued at $9,472,000 after acquiring an additional 16,680 shares during the period. Finally, Intech Investment Management LLC grew its position in shares of ICU Medical by 38.6% in the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock valued at $1,658,000 after acquiring an additional 3,326 shares during the period. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.